Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 105 participants.

Also called NCT01496430

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01496430
  • WHO UTN U1111-1125-1197
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01496430. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-05-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
Condition
Hypertension
Condition
Diabetes
Intervention (Drug)
Placebo
Intervention (Drug)
Azilsartan medoxomil
Intervention (Drug)
Azilsartan medoxomil
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01496430
Content hash
23c6f5e2dc20c1a869059f8f588e259e21ec5c2e14570822756dbd8869c6542c